Perspective Therapeutics, Inc. (CATX)
3.115
-0.04
(-1.42%)
USD |
NYAM |
Sep 01, 16:00
3.115
0.00 (0.00%)
After-Hours: 17:02
Perspective Therapeutics Research and Development Expense (Annual) : 70.96M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 70.96M |
| December 31, 2024 | 39.33M |
| December 31, 2023 | 20.33M |
| June 30, 2022 | 2.582M |
| June 30, 2021 | 1.427M |
| June 30, 2020 | 1.126M |
| June 30, 2019 | 1.474M |
| June 30, 2018 | 1.746M |
| June 30, 2017 | 0.965M |
| June 30, 2016 | 0.528M |
| June 30, 2015 | 0.6148M |
| June 30, 2014 | 0.6688M |
| June 30, 2013 | 0.6271M |
| Date | Value |
|---|---|
| June 30, 2012 | 0.7306M |
| June 30, 2011 | 0.4653M |
| June 30, 2010 | 0.341M |
| June 30, 2009 | 0.9587M |
| June 30, 2008 | 1.358M |
| June 30, 2007 | 1.345M |
| June 30, 2006 | 0.4504M |
| June 30, 2005 | 0.1375M |
| June 30, 2004 | 0.0423M |
| September 30, 2002 | |
| September 30, 2001 | |
| September 30, 2000 | 0.0258M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Anika Therapeutics, Inc. | 25.77M |
| MiMedx Group, Inc. | 14.70M |
| ABVC BioPharma, Inc. | 0.1211M |
| Enovis Corp. | 120.33M |
| Edwards Lifesciences Corp. | 1.079B |